First-in-human Phase 1a study of NG-641, a tumour-selective vector expressing a FAP-TAc bispecific antibody and immune enhancer module, in patients with metastatic/advanced epithelial tumours (STAR)

NG-641 - PsiOxus

Opdivo (nivolumab) - Ono Pharma, BMS

https://jitc.bmj.com/content/10/Suppl_2/A793

George Simon 1; Vivek Subbiah 2; Lee Rosen 3; Heinz-Josef Lenz 4; Haeseong Park 5; Minesh Patel 6; David Miles 6; Stephanie Wallis 6; Vladimir Evilevitch 6; David Krige 6; Mark Powell 6; Tom Lillie 6

Oct 6, 2022